[A19-91] Pomalidomide (multiple myeloma) - Addendum to Commission A19-50
Last updated 05.12.2019
Project no.:
A19-91
Commission:
Commission awarded on 29.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Result of dossier assessment:
Conclusion of dossier assessment A19-50 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-50 | Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-12-05 A G-BA decision was published.